Intermittent claudication: New targets for drug development

Drugs

Volumn 73, Issue 10, 2013, Pages 999-1014

  Brass, Eric P ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ADENOVIRUS VECTOR; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ARGININE; ASCORBIC ACID; BERAPROST; CARNITINE; CILOSTAZOL; DIMETHYLARGININASE; FIBROBLAST GROWTH FACTOR 2; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ILOPROST; NAFTIDROFURYL; NITRIC OXIDE; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PLACEBO; PROPIONYLCARNITINE; PROSTAGLANDIN E1; RANOLAZINE; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RECOMBINANT PROTEIN; SCAVENGER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; ANGIOGENESIS; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAPILLARY DENSITY; CARDIOVASCULAR GENE THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELLULAR STRESS RESPONSE; CRITICAL LIMB ISCHEMIA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; EXERCISE; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIC PRECONDITIONING; LEG BLOOD FLOW; METABOLIC REGULATION; MICROCIRCULATION; MICROVASCULATURE; MITOCHONDRIAL MEMBRANE; MORBIDITY; MUSCLE CELL; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE METABOLISM; MUSCLE STRENGTH; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL DISABILITY; PHYSICAL PERFORMANCE; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; SKELETAL MUSCLE; TREADMILL EXERCISE; TREATMENT OUTCOME; VASCULAR RESISTANCE; WALKING DIFFICULTY;

DRUG DESIGN; EXERCISE THERAPY; HUMANS; INTERMITTENT CLAUDICATION; LOWER EXTREMITY; MUSCLE, SKELETAL; RISK FACTORS;

EID: 84879955459     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0078-3     Document Type: Article

References (197)

1. Hiatt WR, Goldstone J, Smith SC Jr, McDermott M, Moneta G, Oka R, et al. Atherosclerotic peripheral vascular disease symposium II: nomenclature for vascular diseases. Circulation. 2008;118(25):2826-9.
2. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1 Pt 2):S1-296.
3. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47(6):1239-312.
4. Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996;94(11):3026-49.
5. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71(3):510-5.
6. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 1998;18(2):185-92.
7. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381-6.
8. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25(6):1172-81.
9. Criqui MH, McClelland RL, McDermott MM, Allison MA, Blumenthal RS, Aboyans V, et al. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010;56(18):1506-12.
10. Bouisset F, Bongard V, Ruidavets JB, Hascoet S, Taraszkiewicz D, Roncalli J, et al. Prognostic usefulness of clinical and subclinical peripheral arterial disease in men with stable coronary heart disease. Am J Cardiol. 2012;110(2):197-202.
11. Aronow WS. Peripheral arterial disease of the lower extremities. Arch Med Sci. 2012;8(2):375-88.
12. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344(21):1608-21.
13. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA J Am Med Assoc. 2009;301(18):1909-19.
14. Subherwal S, Patel MR, Kober L, Peterson ED, Jones WS, Gislason GH, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation. 2012;126(11):1345-54.
15. Breek JC, de Vries J, van Heck GL, van Berge Henegouwen DP, Hamming JF. Assessment of disease impact in patients with intermittent claudication: discrepancy between health status and quality of life. J Vasc Surg. 2005;41(3):443-50.
16. Dumville JC, Lee AJ, Smith FB, Fowkes FG. The health-related quality of life of people with peripheral arterial disease in the community: the Edinburgh Artery Study. Br J Gen Pract. 2004;54(508):826-31.
17. McDermott MM, Mehta S, Liu K, Guralnik JM, Martin GJ, Criqui MH, et al. Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. J Gen Intern Med. 1999;14(3):173-81.
18. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA J Am Med Assoc. 2001;286(13):1599-606.
19. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med. 2002;136(12):873-83.
20. Parr B, Noakes TD, Derman EW. Factors predicting walking intolerance in patients with peripheral arterial disease and intermittent claudication. S Afr Med J. 2008;98(12):958-62.
21. Robbins JL, Jones WS, Duscha BD, Allen JD, Kraus WE, Regensteiner JG, et al. Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. J Appl Physiol. 2011;111(1):81-6.
22. Belch JJ, Mackay IR, Hill A, Jennings P, McCollum P. Oxidative stress is present in atherosclerotic peripheral arterial disease and further increased by diabetes mellitus. Int Angiol. 1995;14(4):385-8.
23. Pipinos II, Judge AR, Selsby JT, Zhu Z, Swanson SA, Nella AA, et al. The myopathy of peripheral arterial occlusive disease: Part 2. Oxidative stress, neuropathy, and shift in muscle fiber type. Vasc Endovasc Surg. 2008;42(2):101-12.
24. Regensteiner JG, Wolfel EE, Brass EP, Carry MR, Ringel SP, Hargarten ME, et al. Chronic changes in skeletal muscle histology and function in peripheral arterial disease. Circulation. 1993;87(2):413-21.
25. Brass EP, Hiatt WR, Green S. Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussion. Vasc Med. 2004;9(4):293-301.
26. Coutinho T, Rooke TW, Kullo IJ. Arterial dysfunction and functional performance in patients with peripheral artery disease: a review. Vasc Med. 2011;16(3):203-11.
27. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(Suppl 1):S1-75.
28. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med. 2002;347(24):1941-51.
29. Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2008(4):CD000990.
30. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA J Am Med Assoc. 1995;274(12):975-80.
31. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol. 1984;56(4):831-8.
32. Short KR, Vittone JL, Bigelow ML, Proctor DN, Coenen-Schimke JM, Rys P, et al. Changes in myosin heavy chain mRNA and protein expression in human skeletal muscle with age and endurance exercise training. J Appl Physiol. 2005;99(1):95-102.
33. Laughlin MH, Roseguini B. Mechanisms for exercise training-induced increases in skeletal muscle blood flow capacity: differences with interval sprint training versus aerobic endurance training. J Physiol Pharmacol. 2008;59(Suppl 7):71-88.
34. Parmenter BJ, Raymond J, Fiatarone Singh MA. The effect of exercise on haemodynamics in intermittent claudication: a systematic review of randomized controlled trials. Sports Med. 2010;40(5):433-47.
35. Duscha BD, Robbins JL, Jones WS, Kraus WE, Lye RJ, Sanders JM, et al. Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients. Arterioscler Thromb Vasc Biol. 2011;31(11):2742-8.
36. Hiatt WR, Regensteiner JG, Wolfel EE, Carry MR, Brass EP. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol. 1996;81(2):780-8.
37. Sorlie D, Myhre K. Effects of physical training in intermittent claudication. Scand J Clin Lab Invest. 1978;38(3):217-22.
38. Beckitt TA, Day J, Morgan M, Lamont PM. Skeletal muscle adaptation in response to supervised exercise training for intermittent claudication. Eur J Vasc Endovasc Surg. 2012;44(3):313-7.
39. Lundgren F, Dahllof AG, Schersten T, Bylund-Fellenius AC. Muscle enzyme adaptation in patients with peripheral arterial insufficiency: spontaneous adaptation, effect of different treatments and consequences on walking performance. Clin Sci (Lond). 1989;77(5):485-93.
40. Celis R, Pipinos II, Scott-Pandorf MM, Myers SA, Stergiou N, Johanning JM. Peripheral arterial disease affects kinematics during walking. J Vasc Surg. 2009;49(1):127-32.
41. Sorkin EM, Markham A. Cilostazol. Drugs Aging. 1999;14(1):63-71 (discussion 2-3).
42. Pande RL, Hiatt WR, Zhang P, Hittel N, Creager MA, McDermott M. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med. 2010;15(3):181-8.
43. Ikeda Y. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Haemost. 1999;82(2):435-8.
44. Yasutake M, Kunimi T, Sato N, Yokoyama H, Sasaki Y, Kusama Y, et al. Effects of a single oral dose of cilostazol on epicardial coronary arteries and hemodynamics in humans. Circ J. 2002;66(3):241-6.
45. Brass EP, Anthony R, Cobb FR, Koda I, Jiao J, Hiatt WR. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006;48(12):2539-45.
46. Brass EP, Cooper LT, Morgan RE, Hiatt WR. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg. 2012;55(2):381-9 e1.
47. Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125(1):130-9.
48. Hedeager Momsen AM, Bach Jensen M, Norager CB, Roerbaek Madsen M, Vestersgaard-Andersen T, Lindholt JS. Quality of life and functional status after revascularization or conservative treatment in patients with intermittent claudication. Vasc Endovasc Surg. 2011;45(2):122-9.
49. Feinglass J, McCarthy WJ, Slavensky R, Manheim LM, Martin GJ. Functional status and walking ability after lower extremity bypass grafting or angioplasty for intermittent claudication: results from a prospective outcomes study. J Vasc Surg. 2000;31(1 Pt 1):93-103.
50. Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 2012;1:CD005262.
51. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012;99(12):1630-8.
52. Dettelbach HR, Aviado DM. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol. 1985;25(1):8-26.
53. Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology. 1993;187(3-5):447-63.
54. Ciuffetti G, Mercuri M, Ott C, Lombardini R, Paltriccia R, Lupattelli G, et al. Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study. Eur J Clin Pharmacol. 1991;41(6):511-5.
55. De Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev. 2008(2):CD001368.
56. de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev. 2012;12:CD001368.
57. Barradell LB, Brogden RN. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging. 1996;8(4):299-322.
58. Mujika I, Padilla S. Detraining: loss of training-induced physiological and performance adaptations. Part I: short term insufficient training stimulus. Sports Med. 2000;30(2):79-87.
59. Zachary I, Morgan RD. Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart. 2011;97(3):181-9.
60. Jones WS, Annex BH. Growth factors for therapeutic angiogenesis in peripheral arterial disease. Curr Opin Cardiol. 2007;22(5):458-63.
61. Volz KS, Miljan E, Khoo A, Cooke JP. Development of pluripotent stem cells for vascular therapy. Vasc Pharmacol. 2012;56(5-6):288-96.
62. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97(12):1114-23.
63. Shyu KG, Chang H, Wang BW, Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med. 2003;114(2):85-92.
64. Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg. 1999;12(2):142-7.
65. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359(9323):2053-8.
66. Creager MA, Olin JW, Belch JJ, Moneta GL, Henry TD, Rajagopalan S, et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation. 2011;124(16):1765-73.
67. Formenti F, Constantin-Teodosiu D, Emmanuel Y, Cheeseman J, Dorrington KL, Edwards LM, et al. Regulation of human metabolism by hypoxia-inducible factor. Proc Natl Acad Sci USA. 2010;107(28):12722-7.
68. Raval Z, Losordo DW. Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. Circ Res. 2013;112(9):1288-302.
69. Epstein SE, Kornowski R, Fuchs S, Dvorak HF. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation. 2001;104(1):115-9.
70. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol. 1992;73(1):346-53.
71. Bylund AC, Hammarsten J, Holm J, Schersten T. Enzyme activities in skeletal muscles from patients with peripheral arterial insufficiency. Eur J Clin Invest. 1976;6(6):425-9.
72. Wang H, Hiatt WR, Barstow TJ, Brass EP. Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease. Eur J Appl Physiol Occup Physiol. 1999;80(1):22-7.
73. Hands LJ, Bore PJ, Galloway G, Morris PJ, Radda GK. Muscle metabolism in patients with peripheral vascular disease investigated by 31P nuclear magnetic resonance spectroscopy. Clin Sci (Lond). 1986;71(3):283-90.
74. Pipinos II, Shepard AD, Anagnostopoulos PV, Katsamouris A, Boska MD. Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle. J Vasc Surg. 2000;31(5):944-52.
75. Bauer TA, Brass EP, Hiatt WR. Impaired muscle oxygen use at onset of exercise in peripheral arterial disease. J Vasc Surg. 2004;40(3):488-93.
76. Bauer TA, Regensteiner JG, Brass EP, Hiatt WR. Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. J Appl Physiol. 1999;87(2):809-16.
77. Barker GA, Green S, Green AA, Walker PJ. Walking performance, oxygen uptake kinetics and resting muscle pyruvate dehydrogenase complex activity in peripheral arterial disease. Clin Sci (Lond). 2004;106(3):241-9.
78. Brass EP, Hiatt WR, Gardner AW, Hoppel CL. Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease. Am J Physiol Heart Circ Physiol. 2001;280(2):H603-9.
79. Pipinos II, Judge AR, Zhu Z, Selsby JT, Swanson SA, Johanning JM, et al. Mitochondrial defects and oxidative damage in patients with peripheral arterial disease. Free Radic Biol Med. 2006;41(2):262-9.
80. Kals J, Kampus P, Kals M, Pulges A, Teesalu R, Zilmer K, et al. Inflammation and oxidative stress are associated differently with endothelial function and arterial stiffness in healthy subjects and in patients with atherosclerosis. Scand J Clin Lab Invest. 2008;68(7):594-601.
81. Bhat HK, Hiatt WR, Hoppel CL, Brass EP. Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease. Circulation. 1999;99(6):807-12.
82. Brass EP, Wang H, Hiatt WR. Multiple skeletal muscle mitochondrial DNA deletions in patients with unilateral peripheral arterial disease. Vasc Med. 2000;5(4):225-30.
83. Pipinos II, Swanson SA, Zhu Z, Nella AA, Weiss DJ, Gutti TL, et al. Chronically ischemic mouse skeletal muscle exhibits myopathy in association with mitochondrial dysfunction and oxidative damage. Am J Physiol Regul Integr Comp Physiol. 2008;295(1):R290-6.
84. Pande RL, Park MA, Perlstein TS, Desai AS, Doyle J, Navarrete N, et al. Impaired skeletal muscle glucose uptake by [18F]fluorodeoxyglucose-positron emission tomography in patients with peripheral artery disease and intermittent claudication. Arterioscler Thromb Vasc Biol. 2011;31(1):190-6.
85. Furnsinn C, Willson TM, Brunmair B. Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia. 2007;50(1):8-17.
86. Rasouli N, Kern PA, Elbein SC, Sharma NK, Das SK. Improved insulin sensitivity after treatment with PPARgamma and PPARalpha ligands is mediated by genetically modulated transcripts. Pharmacogenet Genomics. 2012;22(7):484-97.
87. Sugden MC, Zariwala MG, Holness MJ. PPARs and the orchestration of metabolic fuel selection. Pharmacol Res. 2009;60(3):141-50.
88. Wenz T, Diaz F, Spiegelman BM, Moraes CT. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab. 2008;8(3):249-56.
89. Riserus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008;57(2):332-9.
90. Puigserver P. Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int J Obes (Lond). 2005;29(Suppl 1):S5-9.
91. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 1996;93(1):135-42.
92. Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska-Prokopczuk E, Buros JL, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53(17):1510-6.
93. Ma A, Garland WT, Smith WB, Skettino S, Navarro MT, Chan AQ, et al. A pilot study of ranolazine in patients with intermittent claudication. Int Angiol. 2006;25(4):361-9.
94. Bremer J. Carnitine - metabolism and functions. Physiol Rev. 1983;63(4):1420-80.
95. Bieber LL. Carnitine. Annu Rev Biochem. 1988;57:261-83.
96. Steiber A, Kerner J, Hoppel CL. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med. 2004;25(5-6):455-73.
97. Brevetti G, Chiariello M, Ferulano G, Policicchio A, Nevola E, Rossini A, et al. Increases in walking distance in patients with peripheral vascular disease treated with l-carnitine: a double-blind, cross-over study. Circulation. 1988;77(4):767-73.
98. Brevetti G, di Lisa F, Perna S, Menabo R, Barbato R, Martone VD, et al. Carnitine-related alterations in patients with intermittent claudication: indication for a focused carnitine therapy. Circulation. 1996;93(9):1685-9.
99. Broderick TL, Driedzic W, Paulson DJ. Propionyl-l-carnitine effects on postischemic recovery of heart function and substrate oxidation in the diabetic rat. Mol Cell Biochem. 2000;206(1-2):151-7.
100. Sundqvist KE, Vuorinen KH, Peuhkurinen KJ, Hassinen IE. Metabolic effects of propionate, hexanoate and propionylcarnitine in normoxia, ischaemia and reperfusion. Does an anaplerotic substrate protect the ischaemic myocardium? Eur Heart J. 1994;15(4):561-70.
101. Brevetti G, Perna S, Sabba C, Rossini A, Scotto di Uccio V, Berardi E, et al. Superiority of l-propionylcarnitine vs l-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J. 1992;13(2):251-5.
102. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-l-carnitine in intermittent claudication. J Am Coll Cardiol. 1999;34(5):1618-24.
103. Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, et al. Propionyl-l-carnitine improves exercise performance and functional status in patients with claudication. Am J Med. 2001;110(8):616-22.
104. Hiatt WR, Creager MA, Amato A, Brass EP. Effect of propionyl-l-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease. J Cardiopulm Rehabil Prev. 2011;31(2):125-32.
105. Barker GA, Green S, Askew CD, Green AA, Walker PJ. Effect of propionyl-l-carnitine on exercise performance in peripheral arterial disease. Med Sci Sports Exerc. 2001;33(9):1415-22.
106. Brass EP, Koster D, Hiatt WR, Amato A. A systematic review and meta-analysis of propionyl-l-carnitine effects on exercise performance in patients with claudication. Vasc Med. 2013;18(1):3-12.
107. Sahajwalla CG, Helton ED, Purich ED, Hoppel CL, Cabana BE. Multiple-dose pharmacokinetics and bioequivalence of l-carnitine 330-mg tablet versus 1-g chewable tablet versus enteral solution in healthy adult male volunteers. J Pharm Sci. 1995;84(5):627-33.
108. Evans AM, Fornasini G. Pharmacokinetics of l-carnitine. Clin Pharmacokinet. 2003;42(11):941-67.
109. Pace S, Longo A, Toon S, Rolan P, Evans AM. Pharmacokinetics of propionyl-l-carnitine in humans: evidence for saturable tubular reabsorption. Br J Clin Pharmacol. 2000;50(5):441-8.
110. Rebouche CJ, Engel AG. Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport. J Clin Invest. 1984;73(3):857-67.
111. Brooks DE, McIntosh JE. Turnover of carnitine by rat tissues. Biochem J. 1975;148(3):439-45.
112. Brass EP, Hoppel CL, Hiatt WR. Effect of intravenous l-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans. Clin Pharmacol Ther. 1994;55(6):681-92.
113. Vukovich MD, Costill DL, Fink WJ. Carnitine supplementation: effect on muscle carnitine and glycogen content during exercise. Med Sci Sports Exerc. 1994;26(9):1122-9.
114. Stephens FB, Constantin-Teodosiu D, Laithwaite D, Simpson EJ, Greenhaff PL. Insulin stimulates l-carnitine accumulation in human skeletal muscle. FASEB J. 2006;20(2):377-9.
115. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem. 2003;278(38):36027-31.
116. Drose S, Brandt U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv Exp Med Biol. 2012;748:145-69.
117. Loffredo L, Marcoccia A, Pignatelli P, Andreozzi P, Borgia MC, Cangemi R, et al. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur Heart J. 2007;28(5):608-12.
118. Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, Lunec J. Vitamin C exhibits pro-oxidant properties. Nature. 1998;392(6676):559.
119. Pearson P, Lewis SA, Britton J, Young IS, Fogarty A. The pro-oxidant activity of high-dose vitamin E supplements in vivo. BioDrugs. 2006;20(5):271-3.
120. Carrero JJ, Lopez-Huertas E, Salmeron LM, Baro L, Ros E. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr. 2005;135(6):1393-9.
121. Leng GC, Lee AJ, Fowkes FG, Horrobin D, Jepson RG, Lowe GD, et al. Randomized controlled trial of antioxidants in intermittent claudication. Vasc Med. 1997;2(4):279-85.
122. Violi F, Loffredo L, Mancini A, Marcoccia A. Antioxidants in peripheral arterial disease. Curr Drug Targets. 2003;4(8):651-5.
123. Tornwall ME, Virtamo J, Haukka JK, Aro A, Albanes D, Huttunen JK. The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial. Atherosclerosis. 1999;147(1):193-7.
124. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev. 2000(2):CD000987.
125. Berndt C, Lillig CH, Holmgren A. Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2007;292(3):H1227-36.
126. Dhalla NS, Elmoselhi AB, Hata T, Makino N. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res. 2000;47(3):446-56.
127. Stroher E, Millar AH. The biological roles of glutaredoxins. Biochem J. 2012;446(3):333-48.
128. Gomez-Cabrera MC, Domenech E, Vina J. Moderate exercise is an antioxidant: upregulation of antioxidant genes by training. Free Radic Biol Med. 2008;44(2):126-31.
129. Powers SK, Ji LL, Leeuwenburgh C. Exercise training-induced alterations in skeletal muscle antioxidant capacity: a brief review. Med Sci Sports Exerc. 1999;31(7):987-97.
130. Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord. 2009;24(7):979-83.
131. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124(11):1250-9.
132. Ceconi C, Curello S, Cargnoni A, Ferrari R, Albertini A, Visioli O. The role of glutathione status in the protection against ischaemic and reperfusion damage: effects of N-acetyl cysteine. J Mol Cell Cardiol. 1988;20(1):5-13.
133. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045-51.
134. Nylaende M, Kroese A, Stranden E, Morken B, Sandbaek G, Lindahl AK, et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med. 2006;11(1):21-8.
135. Gans RO, Bilo HJ, Weersink EG, Rauwerda JA, Fonk T, Popp-Snijders C, et al. Fish oil supplementation in patients with stable claudication. Am J Surg. 1990;160(5):490-5.
136. McDermott MM, Liu K, Carr J, Criqui MH, Tian L, Li D, et al. Superficial femoral artery plaque, the ankle-brachial index, and leg symptoms in peripheral arterial disease: the walking and leg circulation study (WALCS) III. Circ Cardiovasc Imaging. 2011;4(3):246-52.
137. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977-87.
138. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002;106(23):2884-7.
139. Matsuo Y, Takumi T, Mathew V, Chung WY, Barsness GW, Rihal CS, et al. Plaque characteristics and arterial remodeling in coronary and peripheral arterial systems. Atherosclerosis. 2012;223(2):365-71.
140. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003;107(5):757-61.
141. Brass EP, Cooper LT, Hanson P, Hiatt WR. Association of clinical attributes and treadmill walking performance in patients with claudication due to peripheral artery disease. J Vasc Surg (in press).
142. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92(6):711-2.
143. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108(12):1481-6.
144. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114(5):359-64.
145. West AM, Anderson JD, Epstein FH, Meyer CH, Wang H, Hagspiel KD, et al. Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. J Am Coll Cardiol. 2011;58(10):1068-76.
146. Bregar U, Poredos P, Sabovic M, Jug B, Sebestjen M. The influence of atorvastatin on walking performance in peripheral arterial disease. Vasa. 2009;38(2):155-9.
147. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858-68.
148. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645-54 (discussion 53-4).
149. Mortensen SP, Damsgaard R, Dawson EA, Secher NH, Gonzalez-Alonso J. Restrictions in systemic and locomotor skeletal muscle perfusion, oxygen supply and VO2 during high-intensity whole-body exercise in humans. J Physiol. 2008;586(10):2621-35.
150. Casey DP, Joyner MJ. Local control of skeletal muscle blood flow during exercise: influence of available oxygen. J Appl Physiol. 2011;111(6):1527-38.
151. Loffredo L, Pignatelli P, Cangemi R, Andreozzi P, Panico MA, Meloni V, et al. Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment. J Vasc Surg. 2006;44(3):525-30.
152. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95(8):2068-74.
153. Bode-Boger SM, Boger RH, Alfke H, Heinzel D, Tsikas D, Creutzig A, et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation. 1996;93(1):85-90.
154. Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K, Frolich JC. Restoring vascular nitric oxide formation by l-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol. 1998;32(5):1336-44.
155. Oka RK, Szuba A, Giacomini JC, Cooke JP. A pilot study of l-arginine supplementation on functional capacity in peripheral arterial disease. Vasc Med. 2005;10(4):265-74.
156. Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med. 2000;5(1):11-9.
157. Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. l-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation. 2007;116(2):188-95.
158. Leiper JM. The DDAH-ADMA-NOS pathway. Ther Drug Monit. 2005;27(6):744-6.
159. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol. 1996;119(8):1533-40.
160. Cooke JP. DDAH: a target for vascular therapy? Vasc Med. 2010;15(3):235-8.
161. Gresele P, Migliacci R, Arosio E, Bonizzoni E, Minuz P, Violi F. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication. J Vasc Surg. 2012;56(6):1622-8.
162. Amendt K. PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis. Angiology. 2005;56(4):409-15.
163. Mohler ER 3rd, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol. 2003;41(10):1679-86.
164. Creager MA, Pande RL, Hiatt WR. A randomized trial of iloprost in patients with intermittent claudication. Vasc Med. 2008;13(1):5-13.
165. Jacobi B, Bongartz G, Partovi S, Schulte AC, Aschwanden M, Lumsden AB, et al. Skeletal muscle BOLD MRI: from underlying physiological concepts to its usefulness in clinical conditions. J Magn Reson Imaging. 2012;35(6):1253-65.
166. McDermott MM, Hoff F, Ferrucci L, Pearce WH, Guralnik JM, Tian L, et al. Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease. J Am Geriatr Soc. 2007;55(3):400-6.
167. Brass EP, Sietsema KE. Considerations in the development of drugs to treat sarcopenia. J Am Geriatr Soc. 2011;59(3):530-5.
168. Sakuma K, Yamaguchi A. Novel intriguing strategies attenuating to sarcopenia. J Aging Res. 2012;2012:251217.
169. Goodman CA, Mayhew DL, Hornberger TA. Recent progress toward understanding the molecular mechanisms that regulate skeletal muscle mass. Cell Signal. 2011;23(12):1896-906.
170. Wang E, Helgerud J, Loe H, Indseth K, Kaehler N, Hoff J. Maximal strength training improves walking performance in peripheral arterial disease patients. Scand J Med Sci Sports. 2010;20(5):764-70.
171. Grizzo Cucato G, de Moraes Forjaz CL, Kanegusuku H, da Rocha Chehuen M, Riani Costa LA, Wolosker N, et al. Effects of walking and strength training on resting and exercise cardiovascular responses in patients with intermittent claudication. Vasa. 2011;40(5):390-7.
172. McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA J Am Med Assoc. 2009;301(2):165-74.
173. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation. 1994;90(4):1866-74.
174. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA. 2006;103(44):16260-5.
175. Moyes CD. Controlling muscle mitochondrial content. J Exp Biol. 2003;206(Pt 24):4385-91.
176. Bhasin S. Testosterone supplementation for aging-associated sarcopenia. J Gerontol A Biol Sci Med Sci. 2003;58(11):1002-8.
177. Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(8):870-8.
178. Sumukadas D, Struthers AD, McMurdo ME. Sarcopenia - a potential target for angiotensin-converting enzyme inhibition? Gerontology. 2006;52(4):237-42.
179. Sumukadas D, Witham MD, Struthers AD, McMurdo ME. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ. 2007;177(8):867-74.
180. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006;144(9):660-4.
181. Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E, Blombery P, et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA J Am Med Assoc. 2013;309(5):453-60.
182. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25(1):17-24.
183. Sanada S, Komuro I, Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol. 2011;301(5):H1723-41.
184. Das M, Das DK. Molecular mechanism of preconditioning. IUBMB Life. 2008;60(4):199-203.
185. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2010;87(3):406-23.
186. Thaveau F, Zoll J, Rouyer O, Chafke N, Kretz JG, Piquard F, et al. Ischemic preconditioning specifically restores complexes I and II activities of the mitochondrial respiratory chain in ischemic skeletal muscle. J Vasc Surg. 2007;46(3):541-7 (discussion 7).
187. Capecchi PL, Pasini FL, Cati G, Colafati M, Acciavatti A, Ceccatelli L, et al. Experimental model of short-time exercise-induced preconditioning in POAD patients. Angiology. 1997;48(6):469-80.
188. McIntosh VJ, Lasley RD. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? J Cardiovasc Pharmacol Ther. 2012;17(1):21-33.
189. Teoh LK, Grant R, Hulf JA, Pugsley WB, Yellon DM. The effect of preconditioning (ischemic and pharmacological) on myocardial necrosis following coronary artery bypass graft surgery. Cardiovasc Res. 2002;53(1):175-80.
190. Semenza GL. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochim Biophys Acta. 2011;1813(7):1263-8.
191. Weerateerangkul P, Chattipakorn S, Chattipakorn N. Roles of the nitric oxide signaling pathway in cardiac ischemic preconditioning against myocardial ischemia-reperfusion injury. Med Sci Monit. 2011;17(2):RA44-52.
192. Geraghty AJ, Welch K. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev. 2011;(6):CD000536.
193. Motovska Z, Knot J, Widimsky P. Stent thrombosis - risk assessment and prevention. Cardiovasc Ther. 2010;28(5):e92-100.
194. Schainfeld RM. Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature. Catheter Cardiovasc Interv. 2002;56(3):421-31.
195. Kiernan TJ, Yan BP, Cruz-Gonzalez I, Cubeddu RJ, Caldera A, Kiernan GD, et al. Pharmacological and cellular therapies to prevent restenosis after percutaneous transluminal angioplasty and stenting. Cardiovasc Hematol Agents Med Chem. 2008;6(2):116-24.
196. Liu TJ, Lai HC, Ting CT, Lee WL. Sustained elevation of circulating vascular endothelial growth factor after percutaneous angioplasty for peripheral arterial diseases. Int J Cardiol. 2006;107(3):415-6.
197. Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR. Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication. Angiology. 1993;44(1):1-10.